Fast In-Field Lab Quality Results
Our mission is to deliver fast, accurate diagnostics anywhere; saving lives and closing the healthcare gap in underserved regions.
350,000
Each year, around 350,000 people in the UK are admitted with suspected heart attacks, but
only 1 in 5 are confirmed.
£2.53 Billion
Cardiovascular disease (CVD) costs the Greater Manchester system an estimated £2.5bn per year.
€48 Million
Adopting pre-hospital diagnostics for low-risk acute coronary syndrome (ACS) patient can save an average of €611 per patient.
1.2 Billion
Approximately 1.2 billion people are at high risk because they lack access to cooling, limiting their ability to safely store vital medical products and food.
The Problem
4 in 5 Chest Pains Are Not Heart Attacks
The Solution
Pre-Hospital Triage Using Our Tool
£2.5 Billion: The Hidden Cost of Heart Disease in Manchester
Cardiovascular disease is costing Greater Manchester £2.5 billion every year, from healthcare and social care to lost productivity and quality of life.
This video breaks down the findings of a major new report and shows why prevention, early diagnosis, and better treatment matter more than ever.
Our Advantages
Cold-Chain-Free Reagents
Our cold-chain-free reagents perform reliably across diverse environments and conditions.
Rapid, Robust, Portable
Our product is rugged, rapid, and reliably accurate wherever results are needed most.
Multi-Test Portable Device
One device. Endless diagnostics. A scalable platform built to grow with your testing needs.
News & Updates
Ideas With Impact Award Winners
Imprinted Diagnostics secures £75,000 funding to advance our portable heart-attack diagnostic platform.
Funding will help us hire a polymer chemist and electrical engineer to deliver early customer projects and build a clinical-ready prototype.
Thank you to the generous donors and The University of Manchester for driving British innovation.
Our Team
Alexander Stokes
Chief Executive Officer |
Dr Alexander Stokes is an engineer and inventor specialising in the commercialisation of cutting-edge sensor technologies. He led the ICURe market validation for a novel point-of-care diagnostic platform, and brings deep expertise in medical diagnostics, biomaterials, and sensor development. His track record includes successful product prototyping and translating innovation into real-world clinical impact.
Marloes Peeters
Chief Scientific Officer |
Professor Marloes Peeters is a leading authority in polymer-based biosensing, with deep expertise in translating academic research into commercial innovation. She has pioneered molecularly imprinted polymers (MIPs) for medical and environmental diagnostics, securing multiple patents and publishing over 90 papers in top-tier scientific journals.
Contact Us